Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ:ARTV
RESEARCH TOOLSreports
Holding ARTV?
Track your performance easily
ARTV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.71 - $17.31
Previous Close$12.78
Volume105.96K
Average Volume (3M)170.44K
Market Cap
$310.39M
Enterprise Value$264.51M
Total Cash (Recent Filing)$62.13M
Total Debt (Recent Filing)$16.26M
Price to Earnings (P/E)―
Beta-1.04
Next Earnings
Aug 29, 2024EPS Estimate
-$1.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding24,287,144
10 Day Avg. Volume77,943
30 Day Avg. Volume170,436
Standard Deviation0.26
R-Squared1.00
Alpha3.10
Financial Highlights & Ratios
Price to Book (P/B)-1.62
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.05K
Enterprise Value/Gross Profit7.90
Enterprise Value/Ebitda-19.78
Forecast
1Y Price Target
$21.25Price Target Upside74.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Options Prices
Currently, No data available
---
Ownership Overview
61.15% Insiders
0.62% Mutual Funds
― Other Institutional Investors
36.24% Public Companies and
Individual Investors
ARTV FAQ
What was Artiva Biotherapeutics, Inc.’s price range in the past 12 months?
Artiva Biotherapeutics, Inc. lowest stock price was $9.71 and its highest was $17.31 in the past 12 months.
What is Artiva Biotherapeutics, Inc.’s market cap?
Currently, no data Available
When is Artiva Biotherapeutics, Inc.’s upcoming earnings report date?
Artiva Biotherapeutics, Inc.’s upcoming earnings report date is Aug 29, 2024 which is 51 days ago.
How were Artiva Biotherapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Artiva Biotherapeutics, Inc. overvalued?
According to Wall Street analysts Artiva Biotherapeutics, Inc.’s price is currently Undervalued.
Does Artiva Biotherapeutics, Inc. pay dividends?
Artiva Biotherapeutics, Inc. does not currently pay dividends.
What is Artiva Biotherapeutics, Inc.’s EPS estimate?
Artiva Biotherapeutics, Inc.’s EPS estimate is -$1.31.
How many shares outstanding does Artiva Biotherapeutics, Inc. have?
Artiva Biotherapeutics, Inc. has 24,287,144 shares outstanding.
What happened to Artiva Biotherapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Artiva Biotherapeutics, Inc.?
Currently, no hedge funds are holding shares in ARTV
---
Artiva Biotherapeutics, Inc. Stock Smart Score
Company Description
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic) rather than a patients own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patients treatment location, making them what we believe to be off-the-shelf. Our lead product candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in an ongoing Phase 1/1b trial in class III or IV lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
---
ARTV Stock 12 Month Forecast
Average Price Target
$21.25
▲(74.61% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Allogene Therapeutics
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Best Analysts Covering ARTV
1 Year
1 Year Success Rate
2/2 ratings generated profit
1 Year Average Return
+15.05%
assigned a buy rating 2 months ago
Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +15.05% per trade.
---